Cognivia Releases New Patient Adherence Solution
Cognivia has announced the launch of its latest solution: Compl-AI©™.
Compl-AI is a predictive tool that helps clinical trial sponsors with patient recruitment and engagement strategies. The new tool scores patient behavior at screening using machine learning. The Compl-AI patient behavior score enables individualized patient engagement strategies. Beyond clinical research, Compl-AI offers healthcare providers an approach to tailor and adjust their patient support for better treatment adherence.
Using Compl-AI, sponsors can detect the risk of non-compliance and drop out risk before the start and monitor it over the course of their clinical trial.
Reference
Cognivia expands its portfolio of predictive solutions introducing Compl-AI©™, an innovative solution that predicts the risk of patient nonadherence & dropout. (2023, May 23). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
